Discovery of new heart failure trigger could change the way cardiovascular drugs are made

July 18, 2012
APJ's yin-yang role in cardiac function: the receptor APJ serves a dual function in heart health, depending on how it’s activated. While APJ enhances heart health upon binding the hormone apelin (green), APJ can also trigger heart enlargement and failure when it senses certain mechanical changes (red). Credit: Sanford-Burnham Medical Research Institute

In their quest to treat cardiovascular disease, researchers and pharmaceutical companies have long been interested in developing new medicines that activate a heart protein called APJ. But researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) and the Stanford University School of Medicine have now uncovered a second, previously unknown, function for APJ—it senses mechanical changes when the heart is in danger and sets the body on a course toward heart failure. This means that activating APJ could actually be harmful in some cases—potentially eye-opening information for some heart drug makers. The study appears July 18 in Nature.

"Just finding a molecule that activates APJ is not enough. What's important to is not if this receptor is 'on' or 'off,' but the way it's activated," said Pilar Ruiz-Lozano, Ph.D., who led the study. Ruiz-Lozano, formerly assistant professor at Sanford-Burnham, is now associate professor of pediatrics in the Stanford University School of Medicine and adjunct faculty member at Sanford-Burnham.

Stretching the heart

APJ is a receptor that sits on the cell surface in many organs, where it senses the external environment. When a hormone called apelin comes along and binds APJ, it sets off a molecular chain reaction that influences a number of cellular functions. Many previous studies have shown that apelin-APJ activity directs beneficial processes such as embryonic heart development, maintenance of normal blood pressure, and new blood vessel formation.

According to Ruiz-Lozano's latest study, however, APJ can also be activated a second, more harmful, way that doesn't involve apelin. In this pathway, APJ senses and responds to mechanical changes in the heart.

To better understand these mechanical changes, let's look at a person with high blood pressure. In this case, the person's heart has to work harder to pump the same amount of blood at the same rate as a healthy person. To meet the increased demand, individual heart muscle cells start making more proteins, making the cells bigger. Eventually, cell membranes stretch and each cell begins to pull away from its neighbor. This leads to an enlarged heart—a condition known as hypertrophy. In pathological (disease) conditions, hypertrophy can lead to heart failure.

APJ and heart failure

The best way to determine the role a plays in a particular cellular process is to see what happens when it's missing. To do this, Ruiz-Lozano's team, including co-first authors Maria Cecilia Scimia, Ph.D. and Cecilia Hurtado, Ph.D., used mice that lack APJ. Under everyday conditions, the APJ-deficient mice appeared perfectly normal. However, unlike their normal counterparts, the mice lacking APJ couldn't sense danger when their hearts enlarged. As a result, mice were actually healthier without APJ—none succumbed to heart failure.

"In other words, without APJ, ignorance is bliss—the heart doesn't sense the danger and so it doesn't activate the hypertrophic pathways that lead to heart failure," Ruiz-Lozano said. "This tells us that, depending on how it's done, activating APJ might make matters worse for disease patients."

Explore further: Taking vitamin E does not impact women's heart failure risk

Related Stories

Taking vitamin E does not impact women's heart failure risk

March 20, 2012
Taking vitamin E supplements does not increase or decrease heart failure risk among women, according to a study in Circulation: Heart Failure, an American Heart Association journal.

Heart hormone helps shape fat metabolism

February 6, 2012
It's well known that exercising reduces body weight because it draws on fat stores that muscle can burn as fuel. But a new study at Sanford-Burnham Medical Research Institute (Sanford-Burnham) suggests that the heart also ...

Mitochondria restructuring protein provides new therapeutic target for heart disease

November 17, 2011
Mitochondria are often called cellular "powerhouses" because they convert nutrients into energy. But these tiny structures also help determine cellular lifespan. Scientists at Sanford-Burnham Medical Research Institute (Sanford-Burnham) ...

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.